JENNIFER ANNE CUTHBERT, MD
Osteopathic Medicine at Harry Hines Blvd, Dallas, TX

License number

Texas F8071

Personal information

See more information about JENNIFER ANNE CUTHBERT at radaris.com

Name

Address

Phone

Jennifer A Cuthbert

5060 Horseshoe Trl, Dallas, TX 75209

(214) 357-3777

Professional information

Jennifer Anne Cuthbert, Dallas TX

Specialties:

Internist

Address:

5323 Harry Hines Blvd, Dallas, TX 75390

Education:

University of Sydney, Sydney Medical School - Doctor of Medicine

Board certifications:

American Board of Internal Medicine Certification in Internal Medicine

Dr. Jennifer A Cuthbert, Dallas TX - MD (Doctor of Medicine)

Specialties:

Internal Medicine

Address:

5201 Harry Hines Blvd, Dallas 75235
(214) 590-8000 (Phone), (214) 590-8341 (Fax)

Certifications:

Internal Medicine, 1981

Awards:

Healthgrades Honor Roll

Languages:

English

Hospitals:

5201 Harry Hines Blvd, Dallas 75235
Parkland Health and Hospital System
5201 Harry Hines Blvd, Dallas 75235
Ut Southwestern University Hospital - Zale Lipshy
5151 Harry Hines Blvd, Dallas 75235

Education:

Medical School
University of Sydney / Faculty of Medicine

Jennifer Anne Cuthbert, Dallas TX

Specialties:

Internal Medicine, Gastroenterology, Hepatology

Work:

Digestive & Liver Diseases
1801 Inwood Rd, Dallas, TX 75235

Education:

University Of Sydney (1973)

Halogenated Mevalonate Compositions And Uses Thereof In Ras-Dependent Cell Growth

US Patent:

5668171, Sep 16, 1997

Filed:

Nov 8, 1993

Appl. No.:

8/148148

Inventors:

Jennifer A. Cuthbert - Dallas TX
Peter E. Lipsky - Dallas TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 3135

US Classification:

514460

Abstract:

Compositions that include as an active ingredient an effective concentration of a halogenated mevalonate preparation, particularly, Fmev (fluoromevalonate) are provided. The pharmacological activity of halogenated mevalonate for inhibiting ras-dependent cell growth, particularly ras-dependent tumor cell growth, is described. Methods for using preparations including a therapeutically effective concentration of Fmev for the inhibition of ras-dependent cell growth, as well as in the treatment and inhibition of ras-dependent tumors is also disclosed. The claimed compositions may be provided in liquid, salve, tablet, or capsule form, as well as other forms suitable for administration to an animal.